Endometrial cancer
Drug research and approvals for endometrial cancer: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 349 studies of endometrial cancer are recruiting on ClinicalTrials.gov, Health Canada has authorized 46 drug trials for it since 2013, FDA has 0 approved and 1 open orphan designations naming it, and the EU has 1 authorised medicine for it.
- Recruiting worldwide: 349
- Trials authorized in Canada: 46
- FDA orphan approvals: 0
- EU medicines: 1
- Improving Rural Endometrial Cancer CareNCT07927244 · Not applicable · UNC Lineberger Comprehensive Cancer Center · starts May 9, 2025
- A KRAS Inhibitor in Participants With Advanced Solid TumorsNCT07912593 · Phase 1 / Phase 2 · Ensem Therapeutics · starts Oct 22, 2026
- CR-002 in Adult Participants With Locally Advanced or Metastatic Solid TumorsNCT07909031 · Phase 1 / Phase 2 · Crescent Biopharma, Inc. · starts Oct 21, 2026
- HB0025-C-0301: A Study to Investigate HB0025 Combined With Chemotherapy as First-Line Treatment for Advanced or…NCT07902999 · Phase 3 · Shanghai Huaota Biopharmaceutical Co., Ltd. · starts Oct 20, 2026
- Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological CancersNCT07902375 · Not applicable · Universiteit Antwerpen · starts Jun 19, 2026
- Feasibility of the "One-Finger Technique" for Identifying the Upper Left Ureter During Para-Aortic LymphadenectomyNCT07895212 · Not applicable · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · starts Jun 26, 2026
- Liquid Biopsy-Based Early Screening for Endometrial Cancer in Regional Chinese PopulationsNCT07892755 · Not reported · Guizhou Provincial People's Hospital · starts Aug 10, 2026
- Radiotherapy for Gynecologic Cancer With Up to 10 Active Metastatic LesionsNCT07883798 · Not reported · Affidea Nu-med Center of Oncological DIagnostics and Therapy · starts Oct 6, 2026
- Safety, Efficacy and Quality of Life After Adjuvant Hypofractionated Radiotherapy for Endometrial CancerNCT07871838 · Not applicable · McGill University Health Centre/Research Institute of the McGill University Health Centre · starts Mar 7, 2025
Approved 2
- PembrolizumabProgrammed cell death protein 1 inhibitor
- DostarlimabProgrammed cell death protein 1 antagonist
Phase 3 12 of 31
- PaclitaxelTubulin inhibitor
- CarboplatinDNA inhibitor
- CisplatinDNA inhibitor
- DoxorubicinDNA topoisomerase II alpha inhibitor
- LetrozoleCytochrome P450 19A1 inhibitor
- DocetaxelTubulin inhibitor
- Medroxyprogesterone acetateProgesterone receptor agonist
- MetforminMitochondrial complex I (NADH dehydrogenase) inhibitor
- Megestrol acetateProgesterone receptor agonist
- LenvatinibVascular endothelial growth factor receptor inhibitor
- OlaparibPARP 1, 2 and 3 inhibitor
- AtezolizumabProgrammed cell death 1 ligand 1 inhibitor
Phase 2 12 of 89
- BevacizumabVascular endothelial growth factor A inhibitor
- EverolimusFK506-binding protein 1A inhibitor
- NiraparibPoly [ADP-ribose] polymerase 2 inhibitor
- Mirvetuximab soravtansineFolate receptor alpha binding agent
- BuparlisibPI3-kinase class I inhibitor
- RidaforolimusSerine/threonine-protein kinase mTOR inhibitor
- TalazoparibPoly [ADP-ribose] polymerase 2 inhibitor
- CabozantinibVascular endothelial growth factor receptor 2 inhibitor
- OxaliplatinDNA inhibitor
- ProgesteroneProgesterone receptor agonist
- TopotecanDNA topoisomerase I inhibitor
- TemsirolimusEndometrioid cancer · FK506-binding protein 1A inhibitor
Phase 1 or earlier 12 of 33
- Denileukin diftitoxEndometrioid cancer · Elongation factor 2 inhibitor
- IrinotecanDNA topoisomerase I inhibitor
- VinorelbineTubulin inhibitor
- Trastuzumab emtansineReceptor protein-tyrosine kinase erbB-2 binding agent
- ImatinibTyrosine-protein kinase ABL inhibitor
- AnastrozoleCytochrome P450 19A1 inhibitor
- IpilimumabCytotoxic T-lymphocyte protein 4 inhibitor
- MiransertibSerine/threonine-protein kinase AKT inhibitor
- DS-7423Serine/threonine-protein kinase mTOR inhibitor
- AvutometinibEndometrioid cancer · Dual specificity mitogen-activated protein kinase kinase 1 inhibitor
- FruquintinibVascular endothelial growth factor receptor inhibitor
- IpatasertibSerine/threonine-protein kinase AKT inhibitor
How its trials ended
1,118 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 170 whose ending is known, 25% met their primary endpoint, 13% missed it and 62% stopped early.
- Ongoing44640%
- Completed, result not reported35632%
- Status unknown14613%
- Stopped: other or unclear585%
- Met its primary endpoint424%
- Stopped: enrollment or feasibility252%
- Missed its primary endpoint222%
- Stopped: sponsor or business decision121%
- Stopped: lack of efficacy61%
- Stopped: funding5<1%
| Sep 23, 2026 | A phase 3, open-label, multicenter, randomized study of raludotatug deruxtecan (MK-5909, r-dxd) with or without bevacizumab versus standard-of-care…Raludotatug deruxtecan (MK-5909) / Avastin (bevacizumab) / Mvasi (bevacizumab) | Merck & Co. (MSD) | Pending |
| Sep 11, 2026 | An open-label, multicenter, 2-part study: a phase 1b dose selection followed by a randomized phase 3 to evaluate the pharmacokinetics, efficacy, and safety of…Jemperli / Dostarlimab sc / ALT-BB4 | GSK | Pending |
| Jul 28, 2026 | A randomized, open-label, multicenter, phase 3 study to investigate GSK5733584 in combination with immune checkpoint inhibition for maintenance treatment of…Mocertatug rezetecan (GSK5733584) / Keytruda / Jemperli | GSK | Ongoing |
| Jul 27, 2026 | An interventional phase 3, open label, randomized study to evaluate efficacy and safety of PF-08634404 in combination with chemotherapy versus pembrolizumab in…PF-08634404 (SSGJ-707) / Keytruda / Carboplatin / Paclitaxel / Docetaxel | Pfizer | Ongoing |
| Mar 18, 2026 | Weight-loss drug for fertility-sparing treatment of atypical hyperplasia and low-grade cancer of the endometrium (we-fierce)Wegovy | Dr. Sarah E. Ferguson, University Health Network | Ongoing |
| Dec 18, 2025 | A randomized, open-label, multicenter, phase 3 study to investigate GSK5733584 compared with chemotherapy in participants with recurrent endometrial cancerGSK5733584 / Paclitaxel / Doxorubicin | GSK | Ongoing |
| Dec 5, 2025 | A phase 3 randomized, open-label study of rinatabart sesutecan (rina-s) versus treatment of investigator’s choice (IC) in patients with endometrial cancer…Rinatabart sesutecan (rina-s) (PRO1184) (GEN1184) / Paclitaxel / Doxorubicin | Genmab | Ongoing |
| Sep 12, 2025 | A phase 3, multicenter, randomized, open-label trial of trastuzumab deruxtecan versus standard of care chemotherapy with or without radiotherapy as adjuvant…Enhertu | Daiichi Sankyo | Ongoing |
| Jul 28, 2025 | Weight-loss drug for fertility-sparing treatment of atypical hyperplasia and low-grade cancer of the endometrium (we-fierce)Levonorgestrel / Tirzepatide | University Health Network | Closed |
| Jul 4, 2025 | A phase III, randomized, open-label, multicenter, global study of puxitatug samrotecan (AZD8205) monotherapy versus physician's choice of chemotherapy in…AZD8205 | AstraZeneca Pharmaceuticals | Ongoing |
| Date | Drug | Sponsor | Status |
|---|---|---|---|
| Jan 12, 2011 | CridanimodTreatment of progesterone receptor negative endometrial cancer in conjunction with progesterone therapy. | Xenetic Biosciences, Inc. | Designated |
| Authorised | Medicine | Holder | EPAR |
|---|---|---|---|
| Apr 21, 2021 | JemperliDostarlimab | GlaxoSmithKline Trading Services Limited | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA